PharmaCyte Biotech, Inc. (PMCB) - OTCQB
  • Dec. 31, 2015, 10:16 AM
    • In a regulatory filing, PharmaCyte Biotech (OTCQB:PMCB -4%) discloses that its has determined that its financial statements for the fiscal year ended April 30, 2015 and the quarters ended July 31, 2015 and October 31, 2015 should no longer be relied upon. It intends to restate the reports to properly account for certain warrants with a cashless exercise option. They were inadvertently accounted for as liabilities instead of equity.
    • Using the equity method of accounting for the fiscal year, liabilities on the balance sheet were overstated by $492,164. The restated amount will be $1,520,366 as of April 30.
    • For the quarter ended July 31, the equity method of accounting increased the net loss to $1,008,467 from $546,164 (liability method of accounting). For the quarter ended October 31, the restated net loss was $1,129,009 versus $1,099,263.
    • The company will also clarify its disclosure of common stock transactions in the footnotes of the consolidated financial statements. The clarification should not have a material impact on the statements.
    • PharmaCyte will refile the restated reports as soon as feasible.
    | Dec. 31, 2015, 10:16 AM | 13 Comments
  • Jan. 7, 2015, 9:46 AM
    | Jan. 7, 2015, 9:46 AM | 18 Comments
  • Dec. 22, 2014, 11:02 AM
    • The FDA designates Nuvilex's (OTCQB:NVLX +12.7%) pancreatic cancer treatment an Orphan Drug for the indication. Among the benefits of the tag is a seven-year period of exclusivity if approved.
    • The treatment combines the company's proprietary cellulose-based encapsulation technology, Cell-in-a-Box, with the cancer prodrug ifosfamide and encapsulated live cells to convert the prodrug into its cancer-killing form. The capsules are placed close to the cancerous tumor to enable the maximum dose to be delivered to the source of the cancer.
    | Dec. 22, 2014, 11:02 AM | 33 Comments
  • Oct. 17, 2014, 4:17 PM
    • Nuvilex (OTCQB:NVLX -2.9%) files an S-3 for a $50M mixed shelf offering.
    | Oct. 17, 2014, 4:17 PM | 17 Comments
  • Jun. 3, 2014, 8:57 AM
    • Nuvilex (NVLX) closes a $50M at-the-market banking agreement with Chardan Capital. The facility will fund late-stage clinical trials with Clinical Network Services in Australia, preclinical studies and clinical trials with Translational Drug Development in pancreatic cancer and diabetes testing and research in Europe.
    | Jun. 3, 2014, 8:57 AM | 9 Comments
  • May 29, 2014, 9:30 AM
    | May 29, 2014, 9:30 AM | 11 Comments
  • May 7, 2014, 9:01 AM
    • Minnesota state senators vote 48-18 in favor of legalizing physician-prescribed medical marijuana. The bill will permit up to 55 dispensing centers around the state although the health commissioner could approve additional sites.
    • Patients could legally possess up to 2.5 ounces of pot to be ingested in pills, oils or vaporized just shy of combustion. Smoking weed would still be illegal.
    • The bill allows for a research study to assess the effects of medical marijuana in pill or liquid form in patients with severe illnesses.
    • The Senate's version differs from the House's version so more work needs to be done before it passes over the Governor's desk.
    | May 7, 2014, 9:01 AM | 6 Comments
  • Mar. 25, 2014, 11:44 AM
    • DirectView Holdings (DIRV) will open a Colorado office in April to support its cannabis industry security and surveillance business.
    • Growlife (PHOT) extends its due diligence completion date to April 4 regarding its technology distribution deal with RXNB.
    • Nuvilex (NVLX) contracts with Austrianova Singapore to perform cGMP-compliant encapsulation of live cells for its inoperable pancreatic cancer clinical trials.
    • IMD Companies (ICBU) implements a network interface into its environmental controller to allow remote grow room monitoring.
    • Supreme Pharmaceuticals (SPRWF) signs a 12-month purchase option agreement for a medical marijuana producer for $1M.
    | Mar. 25, 2014, 11:44 AM | 3 Comments
Company Description
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box" This unique and patented technology will be... More
Sector: Services
Industry: Business Services
Country: United States